Our Company was originally incorporated as “Senores Pharmaceuticals Private Limited” a private limited company under the Companies Act 2013 through certificate of incorporation dated December 26 2017 issued by the Registrar of Companies Central Registration Centre.The name of the Company was thereafter changed to “Senores Pharmaceuticals Limited” upon conversion to a public limited company pursuant to a Board resolution dated August 1 2023 a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24 2023 and the approval of the central government dated September 4 2023 and consequently a fresh certificate of incorporation dated September 4 2023 was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022- Started the domestic business with a launch of the critical care injectables2023- Acquired majority stake in Havix. making it a Subsidiary of our Company- Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited making a Subsidiary of our Company.2024- Launched first CMO product in the US with Jubilant Cadista
| Name | Position |
|---|---|
| Mr. Sanjay Shaileshbhai Majmudar | Chairman |
| Mr. Swapnil Jatinbhai Shah | Managing Director |
| Mr. Chetan Bipinchandra Shah | Whole Time Director & COO |
| Mr. Deval Rajnikant Shah | WholeTime Director & CFO |
| Mr. Hemanshu Nitinchandra Pandya | Non Exe.Non Ind.Director |